Philogen | Sustainability Performance
Philogen is a biotechnology company specializing in the development of targeted therapeutics. The company focuses on addressing unmet medical needs through innovative solutions in the fields of oncology and autoimmune diseases.
1996
Italy
501 - 1,000 employees
Pharmaceuticals
$100M - 500M in revenue
Not profitable
Sustainability Ranking & Industry Benchmark
#4897
Overall#219
in Italy#109
in PharmaceuticalsSustainability Maturity
Sustainability Intent
Overview
Governance
TargetsESG scores and ExclusionsFinancial Data
Business performanceCapital & innovationAnalyst projections
Market cap
Revenue
Controversy level
- Philogen's financial position as a clinical-stage biopharmaceutical company involved significant R&D expenditures with no commercial revenue.
Market cap
Revenue
EBITDA
Operating margin
P/E ratio
Revenue & EBITDA
$73.0MFY2024 revenue
Total Annual
Revenue & EBITDA
($ B)
Annual revenue
EBITDA
3 year change
Margin trends
Margin as % of revenue
Gross margin
Operating margin
Net margin
Powered by illuminem
Free cashflow
Capex
Debt/equity ratio
Return on invested capital
30.0%FY2026
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Analyst revenue estimates & actuals
Analyst consensus vs actuals
($ B)
Actual revenue
Consensus estimates
Estimate only
0.0
▼ 25.5%
0.0
▼ 18.9%
0.1
▼ 58.7%
0.5
2029Powered by illuminem
Sustainability targets and commitments
| Target | Year | Value | Scope | Baseline |
|---|
Progress against targets
Environmental policy coverage
Carbon reduction policy
Not available
Human rights policy
Not available
Recycling policy
Not available
Workplace health & safety policy
Not available
17%
Independent Directors
2 out of 12 incl. management
Overall score
0
Environment
0
Social
0
Governance
0
Exclusion screening
Adult content
Not available
Alcoholic
Not available
Animal testing
Not available
Firearms
Not available
Tobacco
Not available
Gambling
Not available
Nuclear
Not available
